Chronic Myeloid Leukemia (CML)

	06/09/2009	Suboptimal Response of Imatinib 400 mg in Chronic Myeloid Leukaemia Indicates Need for Early Intervention: Presented at EHA - (DGDispatch)
	06/03/2009	Once-Daily Dasatinib Remains Most Effective Dosing Schedule for Patients With Chronic Phase Chronic Myeloid Leukaemia: Presented at ASCO - (DGDispatch)
	05/26/2009	FDA Approves Dasatinib for CML in Patients Resistant, Intolerant to Prior Therapies - (DGNews)
	12/19/2008	Combining 3 Infection Control Measures Reduces Mortality in High-Risk Cancer Patients - (DGNews)
	12/16/2008	Pre-Existing Diabetes in Persons Diagnosed With Cancer Associated With Increased Risk of Death - (DGNews)
	12/15/2008	Lower-Dose Dasatinib Approved for Patients With Chronic Phase CML - (DGNews)
	12/10/2008	Bosutinib Provides a Therapeutic Option for Patients With Chronic Myelogenous Leukaemia or Acute Lymphocytic Leukaemia: Presented at ASH - (DGDispatch)
	12/10/2008	High-Dose Imatinib Achieves Faster Response Than Standard Dose in Chronic-Phase Chronic Myeloid Leukaemia: Presented at ASH - (DGDispatch)
	12/07/2008	Low Toxicity Profile for Long-Term Imatinib Use in Chronic Myeloid Leukaemia: Presented at ASH - (DGDispatch)
	12/07/2008	Dasatinib May Be Effective for Resistant Chronic Myeloid Leukaemia: Presented at ASH - (DGDispatch)
	11/27/2008	Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
	09/15/2008	FDA Approves Granisetron Patch for Chemotherapy-Induced Nausea, Vomiting - (DGNews)
	09/14/2008	Aprepitant Effective Antiemetic in Cancer Patients Regardless of Nausea Risk Factors: Presented at ESMO - (DGDispatch)
	09/09/2008	Many Cancer Patients Receive Insufficient Pain Management Therapy - (DGNews)
	08/21/2008	FDA Investigating Possible Link Between Ezetimibe/Simvastatin and Increased Cancer Risk - (DGNews)
	08/11/2008	Intrabone Injection of Unrelated Cord-Blood Cells Prevents Graft Failure, Aids Haemopoietic Recovery - (DGNews)
	07/31/2008	FDA Clears the Pathwork Tissue of Origin Test - (DGNews)
	07/03/2008	New Treatment Strategy Improves Depression in Patients With Cancer - (DGNews)
	06/25/2008	Activation of LYN Kinase Is Associated With Imatinib Resistance in CML Patients - (DGNews)
	06/17/2008	Dasatinib Benefits Children and Adolescents With Relapsed or Refractory Leukaemia: Presented at EHA - (DGDispatch)
	06/17/2008	Frontline Dasatinib Demonstrates Rapid Response in Patients With Previously Untreated Chronic-Phase Chronic Myeloid Leukaemia: Presented at EHA - (DGDispatch)
	06/17/2008	High-Dose Imatinib Offers No Additional Benefit to Standard Dose as First-Line Therapy for High-Risk Chronic-Phase Chronic Myeloid Leukaemia: Presented at EHA - (DGDispatch)
	06/17/2008	Researchers Evaluate the Role of Chemotherapy at the End of Life - (DGNews)
	06/15/2008	High-Dose Imatinib Followed by Maintenance Not Significantly Different Than Continuous Standard-Dose Imatinib in Patients With Previously Treated Chronic Phase Chronic Myeloid Leukaemia: Presented at EHA - (DGDispatch)
	06/15/2008	High-Dose Imatinib Offers No Benefit as First- Line Therapy for High-Risk Chronic-Phase CML: Presented at EHA - (DGDispatch)
	06/15/2008	Interim Analysis: First-Line Nilotinib Effective in Patients With Chronic Myeloid Leukaemia: Presented at EHA - (DGDispatch)
	06/15/2008	Bosutinib Induces Response in Patients With CML Resistant or Intolerant to Imatinib, Other TKIs: Presented at EHA - (DGDispatch)
	06/15/2008	Dasatinib Benefits Patients With Chronic-Phase CML Failing Imatinib: Presented at EHA - (DGDispatch)
	06/15/2008	High-Dose vs Standard-Dose Imatinib in Treatment-Naive Patients With Newly Diagnosed CML: Presented at EHA - (DGDispatch)
	06/03/2008	Nilotinib Shows 91% Overall Survival at 18 Months in Patients With Chronic Myelogenous Leukaemia Resistant/Intolerant to Imatinib: Presented at ASCO - (DGDispatch)